Clinical characteristics of patients with AML whose samples were used for CAGE analysis
| Patient No. . | IACS-010759 sensitivity . | Diagnosis . | % Blast . | Mutation status . |
|---|---|---|---|---|
| 1 | Sensitive | AML | 78 | NRAS |
| 2 | Sensitive | AML | 74 | CEPBA; BCR-ABL1, E1A2 |
| 3 | Sensitive | AML | 93 | FLT3-ITD, IDH1, NPM1 |
| 4 | Sensitive | AMOL | 76 | DNMT3A, IDH1, NPM1, FLT3-D835+V491L |
| 5 | Sensitive | AML | 19 | EZH2, KRAS, NPM1, TET2, RUNX1 |
| 6 | Sensitive | AML | 52 | FLT3-D835, NPM1 |
| 7 | Sensitive | AML | 96 | NRAS, TET2, AML1-ETO |
| 8 | Sensitive | AML | 64 | GATA2, CEPBA |
| 9 | Sensitive | AML | 94 | FLT3-D835, IDH2, RUNX1, WT1 |
| 10 | Sensitive | AML | 22 | ASXL1, GATA1, JAK2 |
| 11 | Sensitive | AML | 87 | CEPBA, FLT3-ITD, WT1 |
| 12 | Sensitive | AMOL | 73 | IDH2, NPM1 |
| 13 | Sensitive | AML | 58 | DNMT3A, NRAS, TET2 |
| 14 | Sensitive | AML | 15 | ASXL1, IDH1, JAK2 |
| 15 | Sensitive | AML | 23 | CEPBA, ASXL1, EZH2, TET2 |
| 16 | Sensitive | AML | 88 | FLT3-ITD, WT1 |
| 17 | Resistant | AMML | 21 | IDH1, DNMT3A, NPM1, NRAS |
| 18 | Resistant | AML | 18 | Negative |
| 19 | Resistant | AML | 90 | NRAS |
| 20 | Resistant | AML | 80 | DNMT3A, JAK2, KIT, NRAS, RUNX1, TET2, WT1 |
| 21 | Resistant | AML | 34 | Negative |
| 22 | Resistant | AML | 74 | RUNX1, TET2, TP53 |
| 23 | Resistant | AML | 26 | FLT3-D835, NRAS |
| 24 | Resistant | AMML | 17 | TP53 |
| 25 | Resistant | AML | 81 | IDH1, NOTCH1, TP53 |
| 26 | Resistant | AMOL | 90 | DNMT3A, NPM1, NRAS, TET2 |
| Patient No. . | IACS-010759 sensitivity . | Diagnosis . | % Blast . | Mutation status . |
|---|---|---|---|---|
| 1 | Sensitive | AML | 78 | NRAS |
| 2 | Sensitive | AML | 74 | CEPBA; BCR-ABL1, E1A2 |
| 3 | Sensitive | AML | 93 | FLT3-ITD, IDH1, NPM1 |
| 4 | Sensitive | AMOL | 76 | DNMT3A, IDH1, NPM1, FLT3-D835+V491L |
| 5 | Sensitive | AML | 19 | EZH2, KRAS, NPM1, TET2, RUNX1 |
| 6 | Sensitive | AML | 52 | FLT3-D835, NPM1 |
| 7 | Sensitive | AML | 96 | NRAS, TET2, AML1-ETO |
| 8 | Sensitive | AML | 64 | GATA2, CEPBA |
| 9 | Sensitive | AML | 94 | FLT3-D835, IDH2, RUNX1, WT1 |
| 10 | Sensitive | AML | 22 | ASXL1, GATA1, JAK2 |
| 11 | Sensitive | AML | 87 | CEPBA, FLT3-ITD, WT1 |
| 12 | Sensitive | AMOL | 73 | IDH2, NPM1 |
| 13 | Sensitive | AML | 58 | DNMT3A, NRAS, TET2 |
| 14 | Sensitive | AML | 15 | ASXL1, IDH1, JAK2 |
| 15 | Sensitive | AML | 23 | CEPBA, ASXL1, EZH2, TET2 |
| 16 | Sensitive | AML | 88 | FLT3-ITD, WT1 |
| 17 | Resistant | AMML | 21 | IDH1, DNMT3A, NPM1, NRAS |
| 18 | Resistant | AML | 18 | Negative |
| 19 | Resistant | AML | 90 | NRAS |
| 20 | Resistant | AML | 80 | DNMT3A, JAK2, KIT, NRAS, RUNX1, TET2, WT1 |
| 21 | Resistant | AML | 34 | Negative |
| 22 | Resistant | AML | 74 | RUNX1, TET2, TP53 |
| 23 | Resistant | AML | 26 | FLT3-D835, NRAS |
| 24 | Resistant | AMML | 17 | TP53 |
| 25 | Resistant | AML | 81 | IDH1, NOTCH1, TP53 |
| 26 | Resistant | AMOL | 90 | DNMT3A, NPM1, NRAS, TET2 |
AMML, acute myelomonocytic leukemia; AMOL, acute monoblastic leukemia; ITD, internal tandem duplication.